Pharmaceutical industry tactics could be blocking generic drugs

The European Commission has uncovered a 'tool box' of pharmaceutical company strategies that may be delaying availability of cheaper generic alternatives to costly patented medicines.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here